Research and Clinical Trials
Advancing Cardiovascular Medicine Through Research
Improving the Diagnosis and Treatment of Cardiovascular Disease
Clinical Trials
To learn about participating in clinical trials, ask your cardiovascular specialist. Learn more about the leading-edge Cottage Health Research Institute (CHRI).
Connect With CHRI
For more than 15 years, Cottage Heart & Vascular Center clinicians have conducted world-class research to improve the prevention, diagnosis and treatment of heart and vascular disease. The work of our researchers has improved patient care and addressed clinical needs for some of the most challenging cardiovascular issues.
Clinical trials have brought innovative technologies, life-saving devices and expanded medication choices that wouldn’t otherwise be available. Access to clinical trials offers hope for patients by giving people options when they may have otherwise faced limited treatment choices.
Nationally-Recognized Research
Cardiovascular research at Cottage Health covers a spectrum of investigation and encompasses the different areas of cardiovascular expertise of our health care providers. Our research extends to investigational clinical trials (phases III-IV), registries and retrospective studies. Researchers at Cottage conduct industry-sponsored trials as well as investigator-initiated studies.
The Cottage Health Research Institute (CHRI) offers consultation, liaison and administrative resources to researchers to support the translation of clinical and academic research. CHRI works closely with investigators to implement protocols at Cottage Health and assists in participant screening, consenting, enrolling, conducting study visits, and collection and entry of data.
Minimally Invasive Treatment Options
“Our team is one of the most experienced on the West Coast. We were the first to offer a lot of these procedures dating back to 2005. Clinical trials for both TAVR and Watchman—and for PFO (patent foramen ovale) closure—that you couldn’t even get in most academic centers at the time.”
Joseph Aragon, MD, FACC, FSCAI
Cottage Structural Heart Clinic
Cottage Heart & Vascular Center
Learn More
Structural Heart Disease Treatments
“Cottage has a team of experts on the cutting-edge of transcatheter therapies for people with advanced heart disease.”
Michael Shenoda, MD, FACC, FSCAI
Cottage Structural Heart Clinic
Cottage Heart & Vascular Center
Learn More
Current Cardiovascular Clinical Trials
REDUCE-PAS
Study Sponsor: W.L. Gore & Associates, Inc.
Principal Investigator(s): Aragon (PI), Shenoda, Delio
The REDUCE PAS study is a post-approval study assessing the safety and effectiveness of the GORE Septal Occluder device as observed in the REDUCE pivotal IDE study, and evaluating the quality of operator education and training and transferability of trial experience to a post-market setting.
The full study title is “GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study.”
TARGET-IV NA TRIAL
Study Sponsor: Cleveland Clinic
Principal Investigator(s): Aragon (PI), Kumar, Shenoda
The TARGET-IV NA study is a prospective clinical trial for patients undergoing percutaneous coronary intervention. This study will compare the efficacy and safety of the Firehawk™ rapamycin target eluting cobalt chromium coronary stent system to FDA approved drug eluting stent (DES) systems.
CHAMPION – AF
Study Sponsor: Boston Scientific
Principal Investigator(s): Aragon (PI), Cogert, Shenoda, Shafer
CHAMPION-AF is a prospective, randomized, multi-center global investigation. The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
THE START STUDY
Study Sponsor: Renibus Therapeutics, Inc
Principal Investigator(s): Tedesco (PI), Baay
The START study is a phase 2, double-blind, randomized, placebo-controlled investigation. The purpose of this study is to evaluate the effect of RBT-1 (stannous protoporphyrin [SnPP]/iron sucrose [FeS]) on preconditioning response biomarkers in subjects who are at risk for AKI following cardiac surgery.
